Effect on Cellular Immune Function of Treating Gastrointestinal Stromal Tumor by Imatinib Mesylate_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

李云峰 , 李文亮 , 伍治平 , 董建華

Corresponding?author：

Keywords：

甲磺酸伊馬替尼; 胃腸間質瘤; 細胞免疫

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　探討甲磺酸伊馬替尼治療胃腸道間質瘤對患者細胞免疫功能的影響。
方法　對病理診斷明確的16例行甲磺酸伊馬替尼治療的胃腸間質瘤患者的CD3+、CD4+、CD8+、CD4+/CD8+及NK細胞水平進行回顧性分析比較。
結果　16例接受嚴格甲磺酸伊馬替尼治療的患者，其CD3+、CD4+、CD8+、CD4+/CD8+及NK細胞水平在甲磺酸伊馬替尼治療前、后無明顯變化（P gt;0.05）。
結論　采用甲磺酸伊馬替尼在對胃腸間質瘤患者進行分子靶向治療時，對患者的細胞免疫功能無明顯影響。

Citation： 李云峰,李文亮,伍治平,董建華. Effect on Cellular Immune Function of Treating Gastrointestinal Stromal Tumor by Imatinib Mesylate. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2007, 14(6): 707-708. doi: Copy

1.	Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era——a population-based study in western Sweden [Ｊ]. Cancer, 2005; 103(4)∶821.
2.	D’Amato G, Steinert DM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors [Ｊ]. Cancer Control, 2005; 12(1)∶44.
3.	Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis [Ｊ]. Am J Surg Pathol， 1983; 7(6)∶507.
4.	Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract [Ｊ]. Histol Histopathol, 2000; 15(4)∶1293.
5.	Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO [Ｊ]. Ann Oncol, 2005; 16(4)∶566.
6.	Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop [Ｊ]. Hum Pathol, 2001; 32(6)∶578.
7.	劉勇，易瑛，曾濤. 胃腸間質瘤的診治分析(附21例報告) [Ｊ]. 中國普外基礎與臨床雜志, 2006; 13(1)∶100.
8.	Benjamin RS, Rankin C, Fletcher C, et al. Phase Ⅲ dose-randomized study of imatini Mesylate(STI571)for GIST: intergroup S0033 early results(abstract 3271) [Ｊ]. Proc Am Soc Clin Oncol, 2003; 22(1)∶814.
9.	Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor [Ｊ]. N Engl J Med, 2001; 344(14)∶1052.
10.	趙成艷, 馬榮, 王忠利，等.非霍奇金淋巴瘤患者T細胞亞群、NK細胞檢測的臨床意義 [Ｊ]. 中國免疫學雜志， 2006； 22（2）∶180.
11.	Nishioka Y, Wen H, Mitani K, et al. Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide [Ｊ]. J Leukoc Biol, 2003; 73(5)∶621.
12.	皋嵐湘，丁華野，鄧永江, 等. 乳腺癌組織Bcl-2、P53和c-erbB2 蛋白表達和相互關系及意義 [Ｊ]. 中華病理學雜志, 1996; 25(3)∶165.

1. 　Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era——a population-based study in western Sweden [Ｊ]. Cancer, 2005; 103(4)∶821.
2. 　D’Amato G, Steinert DM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors [Ｊ]. Cancer Control, 2005; 12(1)∶44.
3. 　Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis [Ｊ]. Am J Surg Pathol， 1983; 7(6)∶507.
4. 　Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract [Ｊ]. Histol Histopathol, 2000; 15(4)∶1293.
5. 　Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO [Ｊ]. Ann Oncol, 2005; 16(4)∶566.
6. 　Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop [Ｊ]. Hum Pathol, 2001; 32(6)∶578.
7. 　劉勇，易瑛，曾濤. 胃腸間質瘤的診治分析(附21例報告) [Ｊ]. 中國普外基礎與臨床雜志, 2006; 13(1)∶100.
8. 　Benjamin RS, Rankin C, Fletcher C, et al. Phase Ⅲ dose-randomized study of imatini Mesylate(STI571)for GIST: intergroup S0033 early results(abstract 3271) [Ｊ]. Proc Am Soc Clin Oncol, 2003; 22(1)∶814.
9. 　Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor [Ｊ]. N Engl J Med, 2001; 344(14)∶1052.
10. 　趙成艷, 馬榮, 王忠利，等.非霍奇金淋巴瘤患者T細胞亞群、NK細胞檢測的臨床意義 [Ｊ]. 中國免疫學雜志， 2006； 22（2）∶180.
11. 　Nishioka Y, Wen H, Mitani K, et al. Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide [Ｊ]. J Leukoc Biol, 2003; 73(5)∶621.
12. 　皋嵐湘，丁華野，鄧永江, 等. 乳腺癌組織Bcl-2、P53和c-erbB2 蛋白表達和相互關系及意義 [Ｊ]. 中華病理學雜志, 1996; 25(3)∶165.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Effect on Cellular Immune Function of Treating Gastrointestinal Stromal Tumor by Imatinib Mesylate

Abstract Full text Figures/Tables Video References Cited by

Format

Content